Brett Smith1, Dennis Ang1. 1. Section on Rheumatology and Immunology, Wake Forest University School of Medicine, Medical Center Blvd, 3rd Floor, Watlington Hall, Winston Salem, North Carolina, USA.
Abstract
OBJECTIVE: To determine the association of self-report use of metformin and pain intensity. DESIGN: Survey-based cross sectional. SETTING: Primary care in an academic medical center. SUBJECTS: Three hundred and twenty nine participants with diabetes. METHODS: A total of 329 men and women, aged 18-65, completed a phone-based survey. We utilized the Brief Pain Inventory to assess for pain intensity ratings; Leeds Assessment of Neuropathic Symptoms and Signs to screen for neuropathy; and the Personal Health Questionnaire (PHQ8) Depression Scale to assess for depression. RESULTS: Three hundred and twenty nine diabetics (mean age 54- ± 8-year old) completed the study (162 metformin users, 167 nonusers). Compared with non-users, metformin users were used more often [38% vs 20%, P = 0.001]; had lower mean depression scores [6.8 vs 8.3; P = 0.026] and fewer comorbidities [1.5 vs 1.8, P = 0.022]. Adjusting for those three variables, pain scores were not significantly different between groups. In a subset analyses of those with neuropathic pain (n = 156), there were no differences in pain scores found between groups. CONCLUSIONS: In a clinic sample of patients with diabetes, the use of metformin at an average dose of 1,432 mg (SD = 596 mg) was not associated with lower pain scores. Given the anti-nociceptive effects of metformin in the animal models of pain, and the relative safety of metformin, future research should evaluate the effect of the higher dose of metformin as a potential analgesic. Wiley Periodicals, Inc.
OBJECTIVE: To determine the association of self-report use of metformin and pain intensity. DESIGN: Survey-based cross sectional. SETTING: Primary care in an academic medical center. SUBJECTS: Three hundred and twenty nine participants with diabetes. METHODS: A total of 329 men and women, aged 18-65, completed a phone-based survey. We utilized the Brief Pain Inventory to assess for pain intensity ratings; Leeds Assessment of Neuropathic Symptoms and Signs to screen for neuropathy; and the Personal Health Questionnaire (PHQ8) Depression Scale to assess for depression. RESULTS: Three hundred and twenty nine diabetics (mean age 54- ± 8-year old) completed the study (162 metformin users, 167 nonusers). Compared with non-users, metformin users were used more often [38% vs 20%, P = 0.001]; had lower mean depression scores [6.8 vs 8.3; P = 0.026] and fewer comorbidities [1.5 vs 1.8, P = 0.022]. Adjusting for those three variables, pain scores were not significantly different between groups. In a subset analyses of those with neuropathic pain (n = 156), there were no differences in pain scores found between groups. CONCLUSIONS: In a clinic sample of patients with diabetes, the use of metformin at an average dose of 1,432 mg (SD = 596 mg) was not associated with lower pain scores. Given the anti-nociceptive effects of metformin in the animal models of pain, and the relative safety of metformin, future research should evaluate the effect of the higher dose of metformin as a potential analgesic. Wiley Periodicals, Inc.
Entities:
Keywords:
Diabetic Neuropathy; Neuropathic Pain; Neuropathy; Pain Management; Pain Medicine
Authors: Michael D Burton; Dipti V Tillu; Khadijah Mazhar; Galo L Mejia; Marina N Asiedu; Kufreobong Inyang; Travis Hughes; Bo Lian; Gregory Dussor; Theodore J Price Journal: Neuroscience Date: 2017-07-17 Impact factor: 3.590
Authors: Ana López-de-Andrés; José Luis Del Barrio; Valentín Hernández-Barrera; Javier de Miguel-Díez; Isabel Jimenez-Trujillo; María Angeles Martinez-Huedo; Rodrigo Jimenez-García Journal: Diabetes Metab Syndr Obes Date: 2018-07-20 Impact factor: 3.168